AgomAb Therapeutics

Franklin Rooseveltlaan 348 126
9000 Gent
BE
AgomAb Therapeutics
Foundation date
13/04/2017
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Endocrine - nutritional and metabolic diseases
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
Upcoming events
All events-
0310 '23
-
1810 '23
EMDS2023@VIB
Event by: VIB -
1212 '23
BioFIT 2023
Event by: Eurasanté
Latest news
More news-
argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis
Thursday September 21st 2023
Read more
-
Galapagos appoints Simon Sturge to its Board of Directors
Tuesday September 19th 2023
Read more
-
13th Investment for HERAN Partners: Broken String Biosciences (UK)
Tuesday September 19th 2023
Read more